Metir (AIM:MET), the AIM-listed provider of fast-response water and environmental monitoring technology, has received a Project Confirmation Letter from Avanceon Automation & Control covering its Continuous Toxicity Monitoring (CTM) deployment in Qatar.
The letter follows a 20 July stakeholder meeting involving Qatar General Electricity & Water Corporation (Kahramaa), Avanceon and Metir's Modern Water division, which is the sole supplier of the CTM technology.
Kahramaa has confirmed its intention to run the project for at least 10 years and has reset the Phase 1 final delivery milestone to October, releasing an outstanding milestone payment of approximately £161,000 plus a performance payment of roughly £44,000.
The delay stemmed from regional hostilities that disrupted bio-reagent shipments and restricted staff travel to Doha, compounded by Microtox reagent handling issues under high ambient temperatures rather than any instrument fault.
Modern Water is deploying a specialist biochemist to Doha to finalise storage and handling optimisation alongside Avanceon.
Once handover completes, the contract moves into a maintenance phase generating recurring consumables revenue across all 27 installed units, which the board expects to reach roughly £30,000 a month.
A proposed Phase 2 tender for 17 additional units, taking the installed base to 44, could push consumables revenue above £50,000 a month, alongside a planned local Doha laboratory for Microtox reagent production.
"We are pleased to have resolved the project uncertainty during a difficult period of restricted activity in the region," said Bob Moore, Metir's executive chairman and chief executive.
The board expects recurring revenue from consumables supply to begin following handover in the fourth quarter.
News Intelligence what this means for the company
Metir's Modern Water division has cleared a key project milestone in Qatar: Kahramaa (the national utility) issued a formal Project Confirmation Letter, reset final handover to October, and released £205,000 in accumulated payments (£161,000 milestone plus £44,000 performance). The delay—caused by regional disruptions to bio-reagent shipments and reagent handling issues in high heat, not equipment failure—is now resolved. Critically, handover unlocks the recurring revenue model: Kahramaa confirmed a contract term of at least 10 years, and once Phase 1 closes, the 27 installed toxicity monitors will generate consumables revenue the board expects to reach roughly £30,000 per month, scaling to above £50,000 monthly if a proposed Phase 2 (17 additional units) proceeds.
The Qatar contract moves from a lumpy, milestone-driven model to predictable recurring consumables revenue starting Q4, materially improving cash visibility and reducing execution risk on a contract that represents a meaningful revenue stream for an AIM-listed micro-cap. The 10-year term and Phase 2 optionality provide a foundation for scaling, though near-term cash generation depends on October handover delivery and the board's consumables forecast proving accurate.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
